

DAFTAR PUSTAKA

- Anindhita, B., Manikam, N.R.M., 2023. Medical nutrition therapy in hospitalized patients with pemfigus vulgaris. *World Nutr. J.* 7, 14–22. <https://doi.org/10.25220/10.25220/WNJ.V07.i1.0004>
- Askin, O., 2020. A Retrospective Analysis of Pemphigus Vulgaris Patients: Demographics, Diagnosis, Co-morbid Diseases and Treatment Modalities Used. *North. Clin. Istanbul* 7, 597–602. <https://doi.org/10.14744/nci.2020.37039>
- Baican, A., Chiorean, R., Leucuta, D.C., Baican, C., Danescu, S., Ciuce, D., Sitaru, C., 2015. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: A retrospective cohort study. *Orphanet J. Rare Dis.* 10, 1–14. <https://doi.org/10.1186/s13023-015-0263-4>
- Bardazzi, F., Rucci, P., Rosa, S., Loi, C., Iommi, M., Altobrando, A. Di, 2021. Comorbid diseases associated with pemphigus: a case-control study. *J Dtsch Dermatol Ges* 19, 1613–1619. <https://doi.org/10.1111/ddg.14595>
- Boulard, C., Duvert Lehembre, S., Picard-Dahan, C., Kern, J.S., Zambruno, G., Feliciani, C., Marinovic, B., Vabres, P., Borradori, L., Prost-Squarcioni, C. and Labeille, B., 2016. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. *British journal of dermatology*, 175(1), pp.142-149.
- Cai SC, Zhao X, Tang MB, Lim YL. Epidemiology and Factors Associated with Remission of Pemphigus Vulgaris and Foliaceus in Singapore. *Ann Acad Med Singap.* 2020 Jun;49(6):367-376. PMID: 32712634.
- Chwarscianek, N., Maciaszek, O., Frydrych, Z., Błaszczak, K. and Czajkowski, R., 2025. Metabolic syndrome and skin conditions: Is there a potential link?. In *Forum Dermatologicum* (Vol. 11, No. 2, pp. 83-89).
- Clore, J.N. and Thurby-Hay, L., 2009. Glucocorticoid-induced hyperglycemia. *Endocrine practice*, 15(5), pp.469-474.
- Costello, R.E., Yimer, B.B., Roads, P., Jani, M. and Dixon, W.G., 2021. Glucocorticoid use is associated with an increased risk of hypertension. *Rheumatology*, 60(1), pp.132-139.
- Cunha, S.F.D.C.D., Santos, V.M.D., Monteiro, J.P., Ferreira, T.P.S., Santos, J.A.M.D., Santos, T.A.M.D. and Cunha, D.F.D., 2003. Lípides séricos de pacientes com pênfigo foliáceo sob tratamento prolongado com corticóides. *Revista da Sociedade Brasileira de Medicina Tropical*, 36, pp.1-4.
- Didona, D., Maglie, R., Eming, R., Hertl, M., 2019. Pemphigus: Current and future therapeutic strategies. *Front. Immunol.* 10, 1–28. <https://doi.org/10.3389/fimmu.2019.01418>
- Garg, P., Lakhey, K., Mishra, N., Buccha, Y., Deo, K.S., 2024. Navigating Treatment Dilemmas: Recalcitrant Pemphigus and the Burden of Multiple

- Comorbidities. *Cureus* 16. <https://doi.org/10.7759/cureus.56357>
- Heelan, K., Mahar, A.L., Walsh, S., Shear, N.H., 2015. Pemphigus and associated comorbidities: A cross-sectional study. *Clin. Exp. Dermatol.* 40, 593–599. <https://doi.org/10.1111/ced.12634>
- Hebert, V., Boulard, C., Houivet, E., Lehembre, S.D., Borradori, L., Della Torre, R., Feliciani, C., Fania, L., Zambruno, G., Camaioni, D.B. and Didona, B., 2019. Large international validation of ABSIS and PDAI pemphigus severity scores. *Journal of investigative dermatology*, 139(1), pp.31-37.
- Hsu, D.Y., Brieva, J., Sinha, A.A., Langan, S.M. and Silverberg, J.I., 2016. Comorbidities and inpatient mortality for pemphigus in the USA. *British Journal of Dermatology*, 174(6), pp.1290-1298.
- Hsu, D.Y., Brieva, J., Nardone, B., West, D. and Silverberg, J.I., 2017. Association of pemphigus and systemic corticosteroid use with comorbid health disorders: a case-control study. *Dermatology online journal*, 23(12).
- Ingold, C.J., Sathe, N.C., Khan, M.A., 2024. Pemphigus Vulgaris. StatPearls [Internet].
- Krain, R.L., Bax, C.E., Chakka, S., Ahmed, S., Feng, R., Payne, A.S. and Werth, V.P., 2021. Establishing cut-off values for mild, moderate and severe disease in patients with pemphigus using the Pemphigus Disease Area Index. *British Journal of Dermatology*, 184(5), pp.975-977.
- Kridin, K., Jones, V.A., Patel, P.M., Zelber-Sagi, S., Hammers, C.M., Damiani, G., Amber, K.T., Cohen, A.D., 2020. Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. *Immunol. Res.* 68, 373–378. <https://doi.org/10.1007/s12026-020-09160-6>
- Kridin, K., Zelber-Sagi, S., Bergman, R., 2017. Mortality and cause of death in patients with pemphigus. *Acta Derm. Venereol.* 97, 607–611. <https://doi.org/10.2340/00015555-2611>
- Lemeshow, S., Hosmer Jr, D. W. & Klar, J. 1988. Sample size requirements for studies estimating odds ratios or relative risks. *Statistics in Medicine*, 7, 759-764.
- MartinLepe, K., Yarrarapu, S.N.S., Zito, P.M., 2023. Pemphigus Foliaceus. StatPearls [Internet].
- Mahemuti, N., Jing, X., Zhang, N., Liu, C., Li, C., Cui, Z., Liu, Y. and Chen, J., 2023. Association between systemic immunity-inflammation index and hyperlipidemia: a population-based study from the NHANES (2015–2020). *Nutrients*, 15(5), p.1177.
- Malik, A.M., Tupchong, S., Huang, S., Are, A., Hsu, S., Motaparathi, K., 2021. An updated review of pemphigus diseases. *Med.* 57, 1–15. <https://doi.org/10.3390/medicina57101080>
- Mignard, C., Maho-Vaillant, M., Golinski, M.L., Balayé, P., Prost-Squarcioni, C., Houivet, E., Calbo, S., Labeille, B., Picard-Dahan, C., Konstantinou, M.P. and Chaby, G., 2020. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. *JAMA dermatology*, 156(5), pp.545-552.
- Miyachi, H., Konishi, T., Hashimoto, Y., Matsui, H., Fushimi, K., Inozume, T. and Yasunaga, H., 2023. Clinical course and outcomes of pemphigus vulgaris and

- foliaceus: A retrospective study using a nationwide database in Japan. *The Journal of dermatology*, 50(2), pp.212-221.
- Moro, F., Fania, L., Sinagra, J.L.M., Salemme, A., Di Zenzo, G., 2020. Bullous pemphigoid: Trigger and predisposing factors. *Biomolecules* 10, 1–29. <https://doi.org/10.3390/biom10101432>
- Moro, F., Sinagra, J.L.M., Salemme, A., Fania, L., Mariotti, F., Pira, A., Didona, B., Di Zenzo, G., 2023. Pemphigus: trigger and predisposing factors. *Front. Med.* 10. <https://doi.org/10.3389/fmed.2023.1326359>
- Morsy, H., Zedan, H., Kassim, M., Mwafey, I.M. and Negm, D., 2020. Serum IL-21 level in patients with pemphigus: Before and after treatment. *Dermatologic Therapy*, 33(6), p.e14482.
- Murrell, D.F., Peña, S., Joly, P., Marinovic, B., Hashimoto, T., Diaz, L.A., Sinha, A.A., Payne, A.S., Daneshpazhooh, M., Eming, R., Jonkman, M.F., Mimouni, D., Borradori, L., Kim, S.C., Yamagami, J., Lehman, J.S., Saleh, M.A., Culton, D.A., Czernik, A., Zone, J.J., Fivenson, D., Ujiie, H., Wozniak, K., Akman-Karakaş, A., Bernard, P., Korman, N.J., Caux, F., Drenovska, K., Prost-Squarcioni, C., Vassileva, S., Feldman, R.J., Cardones, A.R., Bauer, J., Ioannides, D., Jedlickova, H., Palisson, F., Patsatsi, A., Uzun, S., Yayli, S., Zillikens, D., Amagai, M., Hertl, M., Schmidt, E., Aoki, V., Grando, S.A., Shimizu, H., Baum, S., Cianchini, G., Feliciani, C., Iranzo, P., Mascaró, J.M., Kowalewski, C., Hall, R., Groves, R., Harman, K.E., Marinkovich, M.P., Maverakis, E., Werth, V.P., 2020. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. *J. Am. Acad. Dermatol.* 82, 575-585.e1. <https://doi.org/10.1016/j.jaad.2018.02.021>
- Pankakoski, A., 2024. The Validity Of Bullous Pemphigoid Diagnosis , Clinical Presentations And Comorbidities Of Bullous Pemphigoid And Pemphigus.
- Pankakoski, A., Kluger, N., Sintonen, H., Panelius, J., 2022. Clinical manifestations and comorbidities of pemphigus: a retrospective case-control study in southern Finland. *Eur J Dermatol* 32, 480–486. <https://doi.org/10.1684/ejd.2022.4266>
- Peraza, D.M. (2024) “Pemphigus Vulgaris.” *Merck Manual*. Available at: <https://www.merckmanuals.com/professional/dermatologic-disorders/bullous-diseases/pemphigus-vulgaris>.
- Pietkiewicz, P., Gornowicz-Porowska, J., Bowszyc-Dmochowska, M. and Dmochowski, M., 2015. A retrospective study of antihypertensives in pemphigus: a still uncharted odyssey particularly between thiols, amides and phenols. *Archives of Medical Science*, 11(5), pp.1021-1027.
- Pollmann, R., Schmidt, T., Eming, R., Hertl, M., 2018. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. *Clin. Rev. Allergy Immunol.* 54. <https://doi.org/10.1007/s12016-017-8662-z>
- Popko, K., Gorska, E., Stelmaszczyk-Emmel, A., Plywaczewski, R., Stoklosa, A., Gorecka, D., Pyrzak, B. and Demkow, U., 2010. Proinflammatory cytokines Il-6 and TNF- α and the development of inflammation in obese subjects. *European journal of medical research*, 15(Suppl 2), p.120.
- Quintarelli, L., Coi, A., Maglie, R., Corrà, A., Mariotti, E.B., Aimo, C., Ruffo di Calabria, V., Verdelli, A., Bianchi, B., Del Bianco, E., Antiga, E., Caproni, M.,

2022. Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study. *Front. Immunol.* 13, 1–10. <https://doi.org/10.3389/fimmu.2022.895490>
- Rahbar, Z., Daneshpazhooh, M., Mirshams-Shahshahani, M., Esmaili, N., Heidari, K., Aghazadeh, N., Hejazi, P., Ghajarzadeh, M. and Chams-Davatchi, C., 2014. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. *JAMA dermatology*, 150(3), pp.266-272.
- Rezazadeh, F., Moshaverinia, M., Handjani, F., Khoshkholgh, F., Saki, N. and Heiran, A., 2020. The evaluation of serum lipids profile in patients with pemphigus vulgaris: a case-control study. *The Malaysian Journal of Medical Sciences: MJMS*, 27(2), p.57.
- Rokni, A.M., Ayasse, M., Ahmed, A., Guggina, L., Kantor, R.W. and Silverberg, J.I., 2023. Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis. *Archives of dermatological research*, 315(2), pp.207-213.
- Shah, A.A., Dey-Rao, R., Seiffert-Sinha, K. and Sinha, A.A., 2016. Increased oxidative stress in pemphigus vulgaris is related to disease activity and HLA-association. *Autoimmunity*, 49(4), pp.248-257.
- Suryawati, N., Praharsini, I.G.A.A., Wardhana, M. and Darmaputra, I.G.N., 2020. A coexistence of pemphigus vulgaris and type II diabetes in geriatric patient: a case report. *Bali Med J*, 9(1), pp.314-7.
- Swarup, S., Ahmed, I., Grigorova, Y. and Zeltser, R., 2024. Metabolic syndrome. In *StatPearls [internet]*. StatPearls Publishing.
- Tsai, S., Clemente-Casares, X., Revelo, X.S., Winer, S. and Winer, D.A., 2015. Are obesity-related insulin resistance and type 2 diabetes autoimmune diseases?. *Diabetes*, 64(6), pp.1886-1897.
- Uddin, M.J., Tran, D.K., Hannan, M.A., Rahman, M.A., Moni, A., Lam, N.T., Ngoc, V.T.N. and Chu, D.T., 2022. Autoimmune diseases and metabolic disorders: molecular connections and potential therapeutic targets. In *Translational autoimmunity* (pp. 169-183). Academic Press.
- Ujiiea, H., Yamagamib, J., Takahashic, H., Izumia, K., Iwataa, H., Wangd, G., Sawamurae, D., Amagaic, M., Zillikensf, D., 2021. The pathogeneses of pemphigus and pemphigoid diseases. *J. Dermatol. Sci.* 104, 154–63.
- Valderas, J.M., Starfield, B., Sibbald, B., Salisbury, C., Roland, M., 2009. Defining Comorbidity: Implications for Understanding Health and Health Services. *Ann Fam Med* 7, 357–363. <https://doi.org/10.1370/afm.983>
- Wang, Y., Yu, H. and He, J., 2020. Role of dyslipidemia in accelerating inflammation, autoimmunity, and atherosclerosis in systemic lupus erythematosus and other autoimmune diseases. *Discovery Medicine*, 30(159), pp.49-56.
- Welc, N., Ważniewicz, S., Głuszak, P., Spalek, M., Seraszek-Jaros, A., Jałowska, M., Dmochowski, M., 2024. Clinical Characteristics, Comorbidities, and Treatment in Patients with Pemphigus—A Single-Center Retrospective Study. *Antibodies* 13. <https://doi.org/10.3390/antib13040103>

- Yamagami, J., 2018. Recent advances in the understanding and treatment of pemphigus and pemphigoid. *F1000Research* 7, 1–8. <https://doi.org/10.12688/f1000research.14474.1>
- Yesilova, Y., Ucmak, D., Selek, S., Dertlioğlu, S.B., Sula, B., Bozkus, F. and Turan, E., 2013. Oxidative stress index may play a key role in patients with pemphigus vulgaris. *Journal of the European Academy of Dermatology and Venereology*, 27(4), pp.465-467.